← All stocks

Summit Therapeutics Inc.

SMMTPharmaceuticalsLatest filing used: 2026-11-04Filings on SEC EDGAR ↗

Fair value per share

No filings-based value

The company files as a foreign issuer (Form 20-F or 40-F), which this method does not read.

Last close

$14.14

Nov 13, 2026

How we decide

Ten years of results

Revenue

$0 in FY2024

FY2019: $57MFY2020: $860,000FY2021: $2MFY2022: $705,000FY2023: $0FY2024: $0$30M$60MFY19FY21FY24$0
Show as table
YearRevenue
FY2019$57M
FY2020$860,000
FY2021$2M
FY2022$705,000
FY2023$0
FY2024$0

Shares outstanding

Share count rose 4071% over 5 years

FY2019: 17MFY2020: 70MFY2021: 132MFY2022: 193MFY2023: 620MFY2024: 719M0400M800MFY19FY21FY24718.5M
Show as table
YearShares outstanding
FY201917M
FY202070M
FY2021132M
FY2022193M
FY2023620M
FY2024719M

No cash earnings in the filings. No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-11-04. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13.